Savara (SVRA) EPS (Weighted Average and Diluted) (2021 - 2026)
Savara (SVRA) reported EPS (Weighted Average and Diluted) of -$0.15 for Q1 2026, down 25.0% year-over-year from -$0.2 in Q1 2025, and down 15.38% quarter-over-quarter from -$0.13 in Q4 2025.
Savara (SVRA) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Savara (SVRA) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.15 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.15, down 25.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.56 (down 16.67% YoY), and the FY2025 annual result was -$0.53, down 10.42% from the prior year.
- EPS (Weighted Average and Diluted) slipped to -$0.15 in Q1 2026 per SVRA's latest filing, from -$0.13 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.05 in Q1 2022 and troughed at -$0.15 in Q1 2026.
- A 5-year average of -$0.1 and a median of -$0.11 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2024: EPS (Weighted Average and Diluted) increased 14.29% in 2022, then tumbled 71.43% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.07 in 2022, then fell by 14.29% to -$0.08 in 2023, then tumbled by 62.5% to -$0.13 in 2024, then changed by 0.0% to -$0.13 in 2025, then declined by 15.38% to -$0.15 in 2026.
- Business Quant data shows SVRA's EPS (Weighted Average and Diluted) at -$0.15 in Q1 2026, -$0.13 in Q4 2025, and -$0.14 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | -0.15 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.15 |
| Dec 31, 2025 | -0.13 |
| Sep 30, 2025 | -0.14 |
| Jun 30, 2025 | -0.14 |
| Mar 31, 2025 | -0.12 |
| Dec 31, 2024 | -0.13 |
| Sep 30, 2024 | -0.11 |
| Jun 30, 2024 | -0.12 |
| Mar 31, 2024 | -0.11 |
| Dec 31, 2023 | -0.08 |
| Sep 30, 2023 | -0.10 |
| Jun 30, 2023 | -0.07 |
| Mar 31, 2023 | -0.07 |
| Dec 31, 2022 | -0.07 |
| Sep 30, 2022 | -0.07 |
| Jun 30, 2022 | -0.06 |
| Mar 31, 2022 | -0.05 |
| Dec 31, 2021 | -0.07 |
| Sep 30, 2021 | -0.07 |
| Jun 30, 2021 | -0.07 |